Beta Kallikrein B, also known as plasma prekallikrein or Fletcher factor, is a protease enzyme that plays a crucial role in the blood coagulation pathway. It is a zymogen form of kallikrein that circulates in the plasma. It is synthesized primarily in the liver and is released into the bloodstream where it remains in an inactive state until activated by specific stimuli.
When activated, beta kallikrein B undergoes proteolytic cleavage to generate kallikrein, an active serine protease. Kallikrein then initiates the formation of a cascade of reactions leading to the production of bradykinin, a potent vasodilator, and also activates other clotting factors, ultimately contributing to blood clotting.
Beta kallikrein B is an essential component of the intrinsic blood clotting pathway, which is responsible for the formation of clots within blood vessels. It works in conjunction with other factors, such as Factor XII, high molecular weight kininogen (HK), and coagulation factor XI.
Deficiencies or abnormalities in beta kallikrein B can lead to a rare hereditary disorder known as prekallikrein deficiency or Fletcher factor deficiency. This condition is characterized by an increased risk of bleeding, particularly in response to trauma or surgery. Individuals with deficiencies in beta kallikrein B may require specific medical interventions to mitigate bleeding risks.
In summary, beta Kallikrein B is an enzymatic protein circulating in the blood, crucially involved in the clotting process and initiating a cascade of reactions leading to the formation of blood clots.
